Illumina (NASDAQ:ILMN) Trading 4.4% Higher – Still a Buy?

Posted by Francis Steltz on Sep 17th, 2026

Shares of Illumina, Inc. (NASDAQ:ILMN – Get Free Report) rose 4.4% during trading on Tuesday . The company traded as high as $216.23 and last traded at $217.43. Approximately 428,010 shares changed hands during trading, a decline of 77% from the average daily volume of 1,894,535 shares. The stock had previously closed at $208.21.

Analysts Set New Price Targets

Several research firms have issued reports on ILMN. Guggenheim lifted their price target on shares of Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. JPMorgan Chase & Co. raised their price target on shares of Illumina from $220.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Citigroup boosted their target price on Illumina from $95.00 to $113.00 and gave the company a “sell” rating in a research note on Monday, August 3rd. Royal Bank Of Canada increased their price target on shares of Illumina from $170.00 to $230.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Illumina in a research note on Monday, August 31st. Ten analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $199.12.

Read Our Latest Analysis on Illumina

Illumina Price Performance

The company’s 50 day simple moving average is $202.61 and its two-hundred day simple moving average is $164.50. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The stock has a market capitalization of $34.57 billion, a P/E ratio of 42.71, a PEG ratio of 3.15 and a beta of 1.46.

Illumina (NASDAQ:ILMN – Get Free Report) last announced its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. Illumina’s quarterly revenue was up 9.4% on a year-over-year basis. During the same period in the prior year, the business earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities analysts expect that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Insider Buying and Selling at Illumina

In other Illumina news, SVP Christensen Wedel sold 1,033 shares of Illumina stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total transaction of $197,840.16. Following the completion of the transaction, the senior vice president directly owned 14,023 shares of the company’s stock, valued at $2,685,684.96. The trade was a 6.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 119,501 shares of the company’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $218.40, for a total value of $26,099,018.40. Following the completion of the transaction, the director directly owned 770,350 shares in the company, valued at $168,244,440. The trade was a 13.43% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 2,062,465 shares of company stock worth $436,589,802 over the last ninety days. 2.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Illumina

Several hedge funds have recently bought and sold shares of the company. Tidal Investments LLC grew its holdings in shares of Illumina by 10.3% during the 2nd quarter. Tidal Investments LLC now owns 93,728 shares of the life sciences company’s stock valued at $16,480,000 after purchasing an additional 8,726 shares during the last quarter. MCF Advisors LLC boosted its holdings in Illumina by 172.4% in the second quarter. MCF Advisors LLC now owns 158 shares of the life sciences company’s stock valued at $28,000 after acquiring an additional 100 shares during the last quarter. National Pension Service boosted its position in Illumina by 246.7% during the second quarter. National Pension Service now owns 369,856 shares of the life sciences company’s stock valued at $65,032,000 after acquiring an additional 263,172 shares during the last quarter. WINTON GROUP Ltd acquired a new stake in shares of Illumina during the 2nd quarter worth approximately $6,041,000. Finally, NewEdge Advisors LLC increased its position in Illumina by 8.6% in the 2nd quarter. NewEdge Advisors LLC now owns 4,740 shares of the life sciences company’s stock valued at $833,000 after buying an additional 377 shares in the last quarter. 89.42% of the stock is owned by institutional investors.

Illumina Company Profile

(Get Free Report)

Illumina, Inc develops and manufactures genomic analysis technologies used by researchers, healthcare providers, pharmaceutical companies and other organizations. Its offerings include next-generation DNA sequencing systems, microarray platforms, consumables, laboratory services and bioinformatics software designed to help analyze genetic variation and biological functions.

The company’s sequencing instruments include systems for a range of applications and throughput levels, such as the NovaSeq, NextSeq, MiSeq and iSeq platforms.